Kovač, MD, PhD, V., Zwitter, M., Stanic, K., Rajer, M., Kern, I., Vrankar, M., & Edelbaher, N. (2014). Intercalated chemotherapy and erlotinib for advanced NSCLC: high proportion of complete remissions and prolonged progression-free survival among patients with EGFR activating mutations. Radiology and Oncology, 48(4). Retrieved from https://radioloncol.com/index.php/ro/article/view/2233